In Depth Report Analyzes Three Major and Intertwined Areas of Cancer R&D Antibody Drug Target Leukemias and Lymphomas

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c77768) has announced the addition of “Antibody Drug Targets and Special Focus on Leukemias & Lymphomas” to their offering.

“Antibody Drug Targets and Special Focus on Leukemias & Lymphomas”

In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. This extensive 430+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

Drug targets and their associated antibodies have been analyzed by us according to:

• 34 Different molecular functions of target
• 13 Major signaling pathways
• Cancer stem cells
• Conjugated antibodies
• Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
• 31 Targeted cancer indications
• Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
• Antibody therapeutic companies

Contents:
1 Executive Summary
2 Methodologies
3 Table of Contents
4 Antibody Drug Target Analysis in Oncology: What and Where Are We
 Targeting?
5 Antibody Drug Targets by Molecular Function
6 Antibody Drugs Targeting Signaling Pathways
7 Antibodies Targeting Cancer Stem Cells
8 Targets of Antibody Conjugates
9 Antibody Drug Targets by Three Major Non Immunological Therapeutic
 Effects
10 Antibody Targets and Drugs by Cancer Indications
11 Expression Profiles of Antibody Drug Targets
12 Leukemia: An Introduction
13 Current Treatment Strategies of Leukemia
14 Progress in Current Leukemia Treatment Strategies
15 Key Therapeutic Strategies for Future Leukemia Therapies
16 Competitive Landscape in Leukemia Drug Development: The Late Stage
 Pipeline
17 Current Leukemia Drug Development: The Early Stage Pipeline
18 The Myeloid Malignancies
19 Lymphoma: An Introduction
20 Current Lymphoma Treatment Strategies
21 Progress in Current Lymphoma Treatment Strategies
22 Key Therapeutic Lymphoma Strategies
23 Competitive Landscape in Lymphoma Drug Development: The Late Stage
 Pipeline
24 Current Lymphoma Drug Development: The Early Stage Pipeline
25 Disclaimer
26 Drug Index
27 Company Index
28 Appendix I: Antibody Targets by Companies
29 Appendix II: Drugs Approved for the Treatment of Leukemia: A
 Historical Perspective
30 Appendix III: Selected Companies - Anticancer Pipelines
Accentia BioPharmaceuticals
Biogen Idec
Cell Therapeutics
Cephalon
Chiron Corporation (Now Novartis)
Eli Lilly
Favrille
Genentech
Genitope Corporation
Genmab
Genta
GlaxoSmithKline
Immunomedics
Inex Pharmaceuticals
Millennium Pharmaceuticals
Protein Design Labs
Roche
Sanofi-Aventis
Seattle Genetics
Wyeth
3.1 List of Figures
3.2 List of Tables
3.3 List of Boxes

For more information visit http://www.researchandmarkets.com/reports/c77768